Pharmaceutical Substances - Version 4.11

The version 4.11 of Pharmaceutical Substances was launched in September 2021.

This release is focused on 14 new active pharmaceutical ingredients (APIs) and includes many drug products that have innovative mechanism of action as well as fast track and breakthrough status.

Molnupiravir/Lagevrio ™ from MSD was recently approved in the UK by the MHRA as first oral antiviral medicine against symptomatic COVID-19.

New anticancer drugs such as Sotorasib/Amgen as first RAS-inhibitor and further specific kinase inhibitors such as Infigratinib/Bridge Bio Pharma, Tivozanib/AVEO Oncology and Trilaciclib/G1 Therapeutics as chemoprotectant were covered in this update. Relugolix from Takeda/Myovant/Gideon Richter was approved as non-peptidic hormone antagonist for oral treatment of prostate cancer.

Accelerated approval was also received by the cardiovascular drug Vericiguat from Bayer/MSD as first soluble guanylate cyclase stimulator.

As new oral immunosuppressives Ponesimod/Janssen as well as Diroximel fumarate from Biogen were launched for treatment of multiple sclerosis (MS).

Further progress was also achieved by Istradefyllin/Kyowa Kirin as a first generation adenosine antagonist for treatment of Parkinson`s disease and Risdiplam/Roche against spinal muscular atrophy.

Additionally, you will find new entries such as the analgesic Oliceridine/Trevana, Lemborexant/Eisai for treatment of insomnia as well as Triheptanoin/Ultragenyx for fatty acid disorders and further updated APIs in this latest release.

Axel Kleemann, Bernhard Kutscher and Dietmar Reichert

New APIs